Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment.
METHODS: Children with HIV/tuberculosis coinfection weighing 3.0 to 19.9 kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment.
RESULTS: Of 20 children enrolled; 15, 1-7 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir/ritonavir co-administered with rifampicin (n = 15; area under the curve 0-24 55.32 mg/h/L [0.30-398.7 mg/h/L]; C max 3.04 mg/L [0.03-18.6 mg/L]; C 8hr 0.90 mg/L [0.01-13.7 mg/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve 24 121.63 mg/h/L [2.56-487.3 mg/h/L]; C max 9.45 mg/L [0.39-26.4 mg/L]; C 12hr 3.03 mg/L [0.01-17.7 mg/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations ≥1mg/L.
CONCLUSIONS: Modified 8-hourly dosing of lopinavir/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Pediatric infectious disease journal - 42(2023), 10 vom: 01. Okt., Seite 899-904 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chabala, Chishala [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
2494G1JF75 |
|---|
| Anmerkungen: |
Date Completed 22.09.2023 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/INF.0000000000004047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360061877 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360061877 | ||
| 003 | DE-627 | ||
| 005 | 20240313233538.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/INF.0000000000004047 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM360061877 | ||
| 035 | |a (NLM)37506295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chabala, Chishala |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment | ||
| 520 | |a METHODS: Children with HIV/tuberculosis coinfection weighing 3.0 to 19.9 kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment | ||
| 520 | |a RESULTS: Of 20 children enrolled; 15, 1-7 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir/ritonavir co-administered with rifampicin (n = 15; area under the curve 0-24 55.32 mg/h/L [0.30-398.7 mg/h/L]; C max 3.04 mg/L [0.03-18.6 mg/L]; C 8hr 0.90 mg/L [0.01-13.7 mg/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve 24 121.63 mg/h/L [2.56-487.3 mg/h/L]; C max 9.45 mg/L [0.39-26.4 mg/L]; C 12hr 3.03 mg/L [0.01-17.7 mg/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations ≥1mg/L | ||
| 520 | |a CONCLUSIONS: Modified 8-hourly dosing of lopinavir/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Rifampin |2 NLM | |
| 650 | 7 | |a VJT6J7R4TR |2 NLM | |
| 650 | 7 | |a Lopinavir |2 NLM | |
| 650 | 7 | |a 2494G1JF75 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Turkova, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Kapasa, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a LeBeau, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Tembo, Chimuka H |e verfasserin |4 aut | |
| 700 | 1 | |a Zimba, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Weisner, Lubbe |e verfasserin |4 aut | |
| 700 | 1 | |a Zyambo, Khozya |e verfasserin |4 aut | |
| 700 | 1 | |a Choo, Louise |e verfasserin |4 aut | |
| 700 | 1 | |a Chungu, Chalilwe |e verfasserin |4 aut | |
| 700 | 1 | |a Lungu, Joyce |e verfasserin |4 aut | |
| 700 | 1 | |a Mulenga, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Crook, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gibb, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a McIlleron, Helen |e verfasserin |4 aut | |
| 700 | 0 | |a SHINE trial team |e verfasserin |4 aut | |
| 700 | 1 | |a Gibb, Diana M |e investigator |4 oth | |
| 700 | 1 | |a Turkova, Anna |e investigator |4 oth | |
| 700 | 1 | |a Crook, Angela M |e investigator |4 oth | |
| 700 | 1 | |a Choo, Louise |e investigator |4 oth | |
| 700 | 1 | |a Wills, Genevieve |e investigator |4 oth | |
| 700 | 1 | |a Thomason, Margaret J |e investigator |4 oth | |
| 700 | 1 | |a Teera, Jaqueline |e investigator |4 oth | |
| 700 | 1 | |a Owen-Powell, Ellen |e investigator |4 oth | |
| 700 | 1 | |a LeBeau, Kristen |e investigator |4 oth | |
| 700 | 1 | |a Baptiste, David |e investigator |4 oth | |
| 700 | 1 | |a McGowan, Charlotte |e investigator |4 oth | |
| 700 | 1 | |a Spyer, Moira |e investigator |4 oth | |
| 700 | 1 | |a Chabala, Chishala |e investigator |4 oth | |
| 700 | 1 | |a Mulenga, Veronica |e investigator |4 oth | |
| 700 | 1 | |a Lungu, Joyce |e investigator |4 oth | |
| 700 | 1 | |a Kapasa, Monica |e investigator |4 oth | |
| 700 | 1 | |a Zimba, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Zyambo, Khozya |e investigator |4 oth | |
| 700 | 1 | |a Chungu, Chalilwe |e investigator |4 oth | |
| 700 | 1 | |a Tembo, Chimuka |e investigator |4 oth | |
| 700 | 1 | |a Kunda, Sharon |e investigator |4 oth | |
| 700 | 1 | |a Shingalili, Ellen |e investigator |4 oth | |
| 700 | 1 | |a Zulu, Semy |e investigator |4 oth | |
| 700 | 1 | |a Chipoya, Terence |e investigator |4 oth | |
| 700 | 1 | |a Mwanakalanga, Habulembe |e investigator |4 oth | |
| 700 | 1 | |a Chambela, Elias |e investigator |4 oth | |
| 700 | 1 | |a Hankombo, Jessy M |e investigator |4 oth | |
| 700 | 1 | |a Kalumbi, Mox Malama |e investigator |4 oth | |
| 700 | 1 | |a Chola, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Malama, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Wobudeya, Eric |e investigator |4 oth | |
| 700 | 1 | |a Musoke, Philippa |e investigator |4 oth | |
| 700 | 1 | |a Baldwin, Mboizi Robert |e investigator |4 oth | |
| 700 | 1 | |a Nansamba, Winnie |e investigator |4 oth | |
| 700 | 1 | |a Ssenyonga, Mark |e investigator |4 oth | |
| 700 | 1 | |a Ssengooba, Willy |e investigator |4 oth | |
| 700 | 1 | |a Businge, Gerald |e investigator |4 oth | |
| 700 | 1 | |a Hesseling, Anneke C |e investigator |4 oth | |
| 700 | 1 | |a Palmer, Megan |e investigator |4 oth | |
| 700 | 1 | |a van der Zalm, Marieke M |e investigator |4 oth | |
| 700 | 1 | |a Workman, Jessica |e investigator |4 oth | |
| 700 | 1 | |a Demers, Anne-Marie |e investigator |4 oth | |
| 700 | 1 | |a Schaaf, Simon |e investigator |4 oth | |
| 700 | 1 | |a Gie, Robert |e investigator |4 oth | |
| 700 | 1 | |a Walters, Elisabetta |e investigator |4 oth | |
| 700 | 1 | |a Zimri, Warren |e investigator |4 oth | |
| 700 | 1 | |a Hoddinott, Graeme |e investigator |4 oth | |
| 700 | 1 | |a Deventer, Anneen van |e investigator |4 oth | |
| 700 | 1 | |a Goussard, Pierre |e investigator |4 oth | |
| 700 | 1 | |a Morrison, Julie |e investigator |4 oth | |
| 700 | 1 | |a Mave, Vidya |c (PI) |e investigator |4 oth | |
| 700 | 1 | |a Kinikar, Aarti Avinash |e investigator |4 oth | |
| 700 | 1 | |a Raichur, Priyanka |e investigator |4 oth | |
| 700 | 1 | |a Nijampurkar, Aparna |e investigator |4 oth | |
| 700 | 1 | |a Khan, Sameer |e investigator |4 oth | |
| 700 | 1 | |a Hissar, Syed |e investigator |4 oth | |
| 700 | 1 | |a Joseph, Bency |e investigator |4 oth | |
| 700 | 1 | |a Bhavani, Perumal Kannabiran |e investigator |4 oth | |
| 700 | 1 | |a Prathiksha, G |e investigator |4 oth | |
| 700 | 1 | |a Baskaran, Dhanaraj |e investigator |4 oth | |
| 700 | 1 | |a Gomathi, N S |e investigator |4 oth | |
| 700 | 1 | |a Mythily, V |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Hemanth |e investigator |4 oth | |
| 700 | 1 | |a Chelvi, Silambu |e investigator |4 oth | |
| 700 | 1 | |a Sekar, L |e investigator |4 oth | |
| 700 | 1 | |a Hanna, Luke |e investigator |4 oth | |
| 700 | 1 | |a Ramesh, K |e investigator |4 oth | |
| 700 | 1 | |a Latha, Hema |e investigator |4 oth | |
| 700 | 1 | |a Bharathi, S |e investigator |4 oth | |
| 700 | 1 | |a Banu, Parveen |e investigator |4 oth | |
| 700 | 1 | |a Xavier, Dino |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Manjith |e investigator |4 oth | |
| 700 | 1 | |a Guru, K |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Sasi |e investigator |4 oth | |
| 700 | 1 | |a Kesavan, A |e investigator |4 oth | |
| 700 | 1 | |a Gunasundari, A |e investigator |4 oth | |
| 700 | 1 | |a Mangalambal, G |e investigator |4 oth | |
| 700 | 1 | |a Nagarajan, Valarmathi |e investigator |4 oth | |
| 700 | 1 | |a Shankar, Shakeela |e investigator |4 oth | |
| 700 | 1 | |a Selvi, R |e investigator |4 oth | |
| 700 | 1 | |a Vaishnavi, S |e investigator |4 oth | |
| 700 | 1 | |a Yadav, Krishna |e investigator |4 oth | |
| 700 | 1 | |a Supriya, R |e investigator |4 oth | |
| 700 | 1 | |a Giranab, Hema |e investigator |4 oth | |
| 700 | 1 | |a Seetha, A |e investigator |4 oth | |
| 700 | 1 | |a Mary, Stella |e investigator |4 oth | |
| 700 | 1 | |a Gopika, S |e investigator |4 oth | |
| 700 | 1 | |a Rohini, S |e investigator |4 oth | |
| 700 | 1 | |a Revathy, M |e investigator |4 oth | |
| 700 | 1 | |a Balaji, Sarath |e investigator |4 oth | |
| 700 | 1 | |a Elilarasi, S |e investigator |4 oth | |
| 700 | 1 | |a Ganesh, J |e investigator |4 oth | |
| 700 | 1 | |a Aravind, M A |e investigator |4 oth | |
| 700 | 1 | |a Mulambo, Sylvia |e investigator |4 oth | |
| 700 | 1 | |a Mwanyungwi, Hope |e investigator |4 oth | |
| 700 | 1 | |a Tapse, Dharati |e investigator |4 oth | |
| 700 | 1 | |a Sane, Manasi |e investigator |4 oth | |
| 700 | 1 | |a Abdullah, Amina |e investigator |4 oth | |
| 700 | 1 | |a Nakalanzi, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Williams, Cynthia Mukisa |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Pediatric infectious disease journal |d 1991 |g 42(2023), 10 vom: 01. Okt., Seite 899-904 |w (DE-627)NLM012615706 |x 1532-0987 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:10 |g day:01 |g month:10 |g pages:899-904 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/INF.0000000000004047 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 10 |b 01 |c 10 |h 899-904 | ||